Skin and subcutaneous disorders are the 4th leading cause of nonfatal disease burden worldwide, emphasizing the role of dermatology in the ever-expanding field of global health. Skin conditions pose significant impact to patients’ well-being, mental health, ability to function, and social participation.
Through our scientific innovation, we challenge the status quo to reimagine topical dermatology. Our development activities in dermatology we pursue under the project name:
hyliQ® is a unique drug delivery technology designed to truly allow for the first-time cutaneous delivery combined with high bioavailability of a wide range of pharmaceutical drugs. The technology enables the development of superior liquid drug products which are fully absorbed into the stratum corneum using convenient spray or roll-on applicators.
The hyliQ® products are non-greasy and quick-drying, with exceptional cosmetic properties. hyliQ® drugs are water-free and do not require preservatives or penetration enhancers.
Proprietary hyliQ® carrier molecules interact with the natural lipids in the skin and transport the active ingredients through the stratum corneum, into the epidermis, into glands or into hair follicles. By selection of specific carrier molecules, we can customize the properties of our drug products, enhancing targeted penetration into the skin tissues and reducing unwanted side effects.
main dose stays on surface
Low API penetration (<5%)
Greasy, cumbersome to use
Limited compliance
main dose is adsorbed into the skin
Full dose of API can access deeper layers
Small volumes required
Spreads and creeps into cavities and folds
Based on the proprietary hyliQ® technology, we develop the next generation of water-free topical skincare products amplifying dermal bioavailability, supporting the regeneration of the natural skin barriers, and providing an unmatched cosmetic feeling for high patient comfort and compliance.
Our goal is to establish a broad range of novel topical drug products. The novel route of administration of existing therapeutic molecules will offer a better risk-benefit ratio with a significantly improved safety profile, resulting in high patience compliance.